U.S. Drug Overdose Deaths Hit Record High, Opening Door for RBCC to Offer Solutions
HENDERSON, NV / ACCESSWIRE / April 27, 2016 / Recently released overdose mortality statistics paint a grim picture of America's battle against prescription drug addiction, and while the portrait isn't pretty, Rainbow Coral Corp. (OTCQB: RBCC) believes the dire numbers may have at last spurred industry and government to find a workable answer.
According to numbers issued by the Centers for Disease Control (CDC), more than 47,000 people died overall from drug overdoses in the U.S. during 2015. That's the highest total on record. The rising toll spared few. Overdose deaths were up across all gender, racial and ethnic categories. Opioid overdose deaths represented a stunning 60 percent of all overdose fatalities, the CDC said, and the subcategory saw a staggering 14 percent increase over the previous year.
"Those numbers are certainly grim," said RBCC CEO Kimberly Palmer. "However, this overdose epidemic appears to have moved the government to act. Lawmakers now have several bills in the works to combat this scourge. RBCC is doing its part with solutions like Naltrexone, a durable, long-lasting anti-addiction protocol that can help break the overdose cycle, and through our proposed program of opening low-cost, inclusive treatment centers to help the 80 percent of opioid addicts currently shut out of the system. There's a way out of this and RBCC wants to be a leader in that effort."
Research indicates that every dollar invested in effective substance abuse treatment yields government and society a 12-1 ratio of benefits in lower healthcare costs, reduced drug-related crime and decreased criminal justice costs.
For more information on RBCC's initiatives, please visit www.rainbowbiocorp.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.rainbowbiocorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO
info@rainbowcoral.com
SOURCE: Rainbow Coral Corp.
